Trial Profile
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of IGIV-Chromatography (IGIV-C), 10% Treatment in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Immune globulin (Primary)
- Indications Chronic inflammatory demyelinating polyradiculoneuropathy
- Focus Registrational; Therapeutic Use
- Acronyms ICE
- Sponsors Grifols
- 27 Apr 2009 New trial record.
- 23 Apr 2009 Quality of life results presented in a Talecris Biotherapeutics media release.
- 23 Apr 2009 Quality of life results have been published in the April 14, 2009 issue of Neurology, according to a Talecris Biotherapeutics media release.